Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK Parkinson’s drug ‘reduces off time by over two hours per day’

GSK Parkinson’s drug ‘reduces off time by over two hours per day’

5th April 2007

GlaxoSmithKline (GSK) has announced the results of a trial of its Parkinson’s medication Requip (ropinirole HCl) XL 24-Hour extended-release tablets.

The company reports that patients administered with Requip in addition to ongoing levodopa (L-dopa) therapy exhibited a reduction in the period of time characterised by returning symptoms of Parkinson’s as medication wears off, known as ‘off time’.

Requip XL 24-Hour is an orally-administered medication designed to be steadily absorbed by the body to lower the number of changes in plasma over 24 hours and result in a speedier and more simple titration schedule compared with thrice-daily doses of immediate-release Requip.

According to the Ease-PD adjunct study published in Neurology, off time in patients administered with Requip XL 24-Hour was reduced by over two hours when compared to baseline.

Rajesh Pahwa, professor of neurology and director of the Parkinson Disease and Movement Disorder Centre at the University of Kansas Medical Centre, commented that off time is commonly suffered by patients with Parkinson’s, causing problems with movement and simple activity.

“With the investigational Requip XL 24-Hour added to L-dopa, patients can have more than two additional hours per day, on average, without experiencing the disabling symptom of off time,” he said.

Requip is the first compound approved by the US Food and Drug Administration for the treatment of moderate to severe primary restless legs syndrome or Wittmaack-Ekbom’s syndrome.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.